Biotech News

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

Avita Medical (RCEL)Avita MedicalConference / presentation

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026.

AVITA Medical President and CEO Cary Vance will be speaking on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available under the Investor Relations Events & Presentations section of AVITA Medical’s website, at: https://ir.avitamedical.com/events-and-presentations

Investors attending the conference may request a one-on-one meeting with AVITA Medical through their Canaccord Genuity sales representative.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.

In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO® are CE-marked in Europe, have TGA certification in Australia, and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact: Ben Atkins Phone +1-805 341 1571 [email protected] | [email protected]

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

©2026 AVITA Medical. AVITA Medical®, the AVITA Medical logo, Cohealyx®, RECELL®, RECELL GO®, and Spray-On Skin TM Cells are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.

Related news

Avita Medical

Acute Wound Care Company AVITA Medical provides therapies for acute wound care that support wound closure and patient recovery. Its core RECELL platform uses a patient’s own skin to prepare Spray-On Skin Cells for the treatment of thermal burns and traumatic wounds. RECELL and Wound Matrix Portfolio RECELL is FDA-approved in the United...

Recent company news

Stock data

Close
10.06 USD
Market cap
128.95M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States